Abstract
Decreased number and function of beta cells are a key aspect of diabetes mellitus (diabetes), a disease that remains an onerous global health problem. Means of restoring beta cell mass are urgently being sought as a potential cure for diabetes. Several strategies, such as de novo beta cell derivation via pluripotent stem cell differentiation or mature somatic cell transdifferentiation, have yielded promising results. Beta cell expansion is another promising strategy, rendered challenging by the very low proliferative capacity of beta cells. Many effective mitogens have been identified in rodents, but the vast majority do not have similar mitogenic effects in human beta cells. Extensive research has led to the identification of several human beta cell mitogens, but their efficacy and specificity remain insufficient. An approach based on the simultaneous application of several mitogens has recently emerged and can yield human beta cell proliferation rates of up to 8%. Here, we discuss recent advances in restoration of the beta cell population, focusing on mitogen synergy, and the contribution of RNA-sequencing (RNA-seq) to accelerating the elucidation of signaling pathways in proliferating beta cells and the discovery of novel mitogens. Together, these approaches have taken beta cell research up a level, bringing us closer to a cure for diabetes.
Highlights
Diabetes and the Replication of Beta CellsThe beta cells, together with alpha, delta, PP cells and rare epsilon cells, compose the islets of the endocrine pancreas
This study reveals the potential of pharmacological priming of dedifferentiated beta cells for diabetes remission
The review describes recent advances and novel directions in research on human beta cell proliferation, focusing on mitogen synergy and the contribution of RNA-seq technologies. It aims to bring the concept of mitogen synergy to the fore and to provide evidence of its promise as a possible route toward a cure for diabetes
Summary
Diabetes and the Replication of Beta CellsThe beta cells, together with alpha, delta, PP cells and rare epsilon cells, compose the islets of the endocrine pancreas. CHIR99021, a GSK-3 beta inhibitor, in adult human dispersed beta cells did not show mitogenic effects when applied alone, in combination with harmine it increases Ki67 labeling from 0 to 3.5% (Ackeifi et al, 2020a). Many of these mitogens, including harmine, GNF4877, INDY, 5-IT, CC401, and OTS167, have similar mechanisms of action – the inhibition of dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) (Wang et al, 2015b,c; Ackeifi et al, 2020a), highlighting the importance of this protein in beta cell proliferation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.